FibroBiologics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Plans and Arrangements
None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted orterminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report.
Director Departure
On April 29, 2026, Stacy Coen notified our board of directors, or the Board, that she will not be standing for re-election to the Board at our upcoming annual meeting of stockholders on June 22, 2026, or the Annual Meeting. Accordingly, her current term will expire at the conclusion of the Annual Meeting. Ms. Coen’s decision not to stand for re-election is not the result of any disagreement between us and her on any matter relating to our operations, policies or practices.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.